GlassScriptPhysician profile
Harvey C Martin
NPI 1326047556
$5,240.72
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $760 · 2021: $919 · 2022: $962 · 2023: $1,327 · 2024: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $960.64 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $838.17 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $703.57 | 2020-2024 | Caplyta |
| Abbvie INC. | $638.93 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $343.19 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $318.91 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $217.59 | 2019-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $208.95 | 2021-2022 | |
| Corium, LLC | $155.94 | 2022-2024 | Azstarys |
| Indivior INC. | $150.87 | 2022-2024 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $148.56 | 2019-2022 | |
| Allergan, INC. | $129.42 | 2020 | |
| Tris Pharma INC | $104.62 | 2019-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $93.73 | 2019-2023 | Jornay Pm |
| Alkermes, INC. | $84.67 | 2019-2023 | Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34.99 | 2022-2023 | Auvelity |
| Vertical Pharmaceuticals, LLC | $27.74 | 2019 | |
| Lundbeck LLC | $24.95 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $15.94 | 2020 | |
| Neos Therapeutics, LP | $15.67 | 2019 | |
| Neuronetics, INC. | $12.18 | 2020 | |
| Shire North American Group INC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.